Anaconda Biomed — Series A · €15M

Anaconda Biomed closed a €15M Series A (reported by MassDevice as about $17M) co-led by Ysios Capital, Omega Funds and existing investor Innogest Capital, with Banco Sabadell also taking part. The money funded development and clinical studies of its ANCD BRAIN neuro-thrombectomy system. Ysios is listed as lead only because it is named first among three co-leads.

LeadYsios Capital, Omega Funds, Innogest Capital RoundSeries A Announced22 May 2017 CitySant Cugat del Vallès SectorHealthtech & Bio · Medtech / Neurovascular devices Source P

Something wrong? Suggest a correction →